DiaMedica Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from DiaMedica Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 98% of Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 94% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-785.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 98% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-259.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 94% of Healthcare companies in United States.
Cash Cushion Ratio
+13%Cash, after subtracting all debt, equals 13% of its market value (net cash).
Higher than 54% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
DiaMedica Therapeutics Inc. made a loss over the last year. DiaMedica Therapeutics Inc. owes $0.15 for every $1 it owns. DiaMedica Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossDiaMedica Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
12.14The share price is 12.14 times DiaMedica Therapeutics Inc.'s book value per share, higher than 88% of Healthcare companies in United States.
Market cap
$465 MThe total market value of all of DiaMedica Therapeutics Inc.'s shares at today's price (share price × number of shares), larger than 53% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$38 MWhat DiaMedica Therapeutics Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.71Net worth divided by the number of shares. The share price of $8.63 is 12.1 times this, which is the P/B above.
Return on equity (ROE)
-114.6%DiaMedica Therapeutics Inc. lost 114.6% of its shareholders' money over the last year, lower than 75% of Healthcare companies in United States.
Owes vs Owns
0.15×DiaMedica Therapeutics Inc. owes $0.15 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Dividend yield
NoneDiaMedica Therapeutics Inc. does not currently pay a dividend.
Profit growth
LossDiaMedica Therapeutics Inc. made a loss in each of the last two years.
Cash vs debt
Net cashDiaMedica Therapeutics Inc. held $60 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For DiaMedica Therapeutics Inc.: $465 M ÷ $38 M (30 Jun 2026) = 12.1.
What is DiaMedica Therapeutics Inc.'s return on equity?
DiaMedica Therapeutics Inc. lost 114.6% of its shareholders' money over the last year, lower than 75% of Healthcare companies in United States.
How much does DiaMedica Therapeutics Inc. owe compared with what it owns?
DiaMedica Therapeutics Inc. owes $0.15 for every $1 it owns (low), lower than 80% of Healthcare companies in United States.
Does DiaMedica Therapeutics Inc. pay a dividend?
No. DiaMedica Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.